Monte Rosa Therapeutics, Inc.

XNASHealth care

Last traded price · USD

$11.39

+5.27%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:02 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $10.82
Volume: 114
Day's high: —
Day's low: —

In brief

Monte Rosa Therapeutics, Inc. is a health care company listed on Nasdaq, valued at about $972M.
Its shares closed at $10.82 on 4 Nov 2026, down 9.8% over the past year.
From India you can buy GLUE in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Monte Rosa Therapeutics, Inc. (GLUE) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole GLUE share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade GLUE options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: +9.6% (SPY −1.6%, XLV +13.5%). 3 months: −30.7% (SPY −0.4%, XLV +15.5%). 1 year: −9.8% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: GLUE, SPY and XLV · as of 4 Nov 2026
11.2 days to cover short interest
20.7M shares were sold short at the 15 Oct 2026 settlement, 24.2% of the 85.3M shares outstanding; covering them would take 11.2 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
11.8% above its 52-week low
Closed at $10.82 on 4 Nov 2026: 58.0% below the 52-week high of $25.77 (8 Jan 2026) and 11.8% above the low of $9.68 (7 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $10.82 was 8.8% below its 50-day average ($11.86) and 37.0% below its 200-day average ($17.18). It has closed below the 200-day for 68 sessions, since 31 Jul 2026. The 50-day average crossed below the 200-day on 10 Sep 2026, 39 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+9.6%

6 months−46.9%

1 year−9.8%

5 years−58.4%

Newswire

About

Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).

Website

Notable moves

January 7, 2026
+45.41%
September 15, 2025
+44.07%
October 28, 2024
+93.87%

Newswire

About

Website

Notable moves

January 7, 2026
+45.41%
September 15, 2025
+44.07%
October 28, 2024
+93.87%

Monte Rosa Therapeutics, Inc.

XNASHealth care

Last traded price · USD

$11.39

+5.27%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:02 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $10.82
Volume: 114
Day's high: —
Day's low: —

In brief

Monte Rosa Therapeutics, Inc. is a health care company listed on Nasdaq, valued at about $972M.
Its shares closed at $10.82 on 4 Nov 2026, down 9.8% over the past year.
From India you can buy GLUE in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Monte Rosa Therapeutics, Inc. (GLUE) shares from India?

Do I need the price of a whole GLUE share to invest?

How much can I invest in US stocks in a year?

Can I trade GLUE options or futures?

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: +9.6% (SPY −1.6%, XLV +13.5%). 3 months: −30.7% (SPY −0.4%, XLV +15.5%). 1 year: −9.8% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: GLUE, SPY and XLV · as of 4 Nov 2026
11.2 days to cover short interest
20.7M shares were sold short at the 15 Oct 2026 settlement, 24.2% of the 85.3M shares outstanding; covering them would take 11.2 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
11.8% above its 52-week low
Closed at $10.82 on 4 Nov 2026: 58.0% below the 52-week high of $25.77 (8 Jan 2026) and 11.8% above the low of $9.68 (7 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $10.82 was 8.8% below its 50-day average ($11.86) and 37.0% below its 200-day average ($17.18). It has closed below the 200-day for 68 sessions, since 31 Jul 2026. The 50-day average crossed below the 200-day on 10 Sep 2026, 39 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+9.6%

6 months−46.9%

1 year−9.8%

5 years−58.4%

Newswire

About

Website

Notable moves

January 7, 2026
+45.41%
September 15, 2025
+44.07%
October 28, 2024
+93.87%

Newswire

About

Website

Notable moves

January 7, 2026
+45.41%
September 15, 2025
+44.07%
October 28, 2024
+93.87%

Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc. in brief

Behind SPY and its sector fund XLV over 1 year

11.2 days to cover short interest

11.8% above its 52-week low

Below its 50- and 200-day averages

Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc. in brief

Behind SPY and its sector fund XLV over 1 year

11.2 days to cover short interest

11.8% above its 52-week low

Below its 50- and 200-day averages